Karen L. Reckamp, MD, Examines Safety of Ramucirumab Plus Pembrolizumab in IO/Chemo-Pretreated NSCLC

Video
Conference|ASCO Annual Meeting: Lung Cancer

Karen L. Reckamp, MD, spoke about safety signals that emerged in the Lung-MAP nonmatched phase 2 substudy S1800A and what the next steps are for the combination of ramucirumab/pembrolizumab in patients with non–small cell lung cancer pretreated with chemotherapy and immunotherapy

CancerNetwork® spoke with Karen L. Reckamp, MD, director of the Division of Medical Oncology and professor of Medicine at Cedar-Sinai Medical Center, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about the Lung-MAP nonmatched phase 2 substudy S1800A (NCT03971474) in patients with advanced non–small cell lung cancer who were previously treated with immunotherapy and chemotherapy. Investigators set out to determine if ramucirumab (Cyramza) plus pembrolizumab (Keytruda) was superior to standard of care in this population, with a primary end point of overall survival (OS).

The median OS was 14.5 months (80% CI, 13.9-16.1) in the ramucirumab plus pembrolizumab arm vs 11.6 months (80% CI, 9.9-13.0) in the standard of care arm (HR, 0.69; 80% CI, 0.51-0.92; standard log-rank P = .05).

Transcript:

We found that by using a nonchemotherapeutic backbone there were more toxicities in the standard-of-care arm [with] chemotherapy. As we use ramucirumab, we were concerned about vascular toxicity and did see some increase in grade 3 vascular toxicities. These were also seen in the docetaxel plus ramucirumab [arm]. We saw more immune-related adverse events, as you might expect, about 30% of grade 3/4 events [with ramucirumab/pembrolizumab].

We’re excited about these data. This is a randomized phase 2 trial and it shows a robust survival benefit [of ramucirumab/pembrolizumab in this setting]. Obviously, this is a smaller trial and should be confirmed in a larger, randomized phase 3 trial. These are both approved agents, so there may be some benefit to patients thinking about Compendia Listing and potentially moving on to a phase 3 trial that may confirm the results.

Reference

Reckamp KL. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. J Clin Oncol. 2022;40(suppl 16):9004. doi:10.1200/JCO.2022.40.16_suppl.9004

Related Videos
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Related Content
Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Atezolizumab Combo Numerically Improves pCR in HER2+ Operable Breast Cancer

December 9th 2023
Article

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

November 13th 2023
Podcast

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Metabolism, Genetics May Impact Tumor Biology in Breast Cancer Populations

December 8th 2023
Article

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

September 4th 2023
Podcast

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

T-DM1 Improves OS/iDFS Vs Trastuzumab in HER2+ Breast Cancer

December 8th 2023
Article

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Profiling Tests May Predict Chemo Efficacy in Early-Stage Breast Cancer

December 8th 2023
Article

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.